Cytochrome P450 polymorphisms in patients with Behcet's disease

Türsen, Ümit; Tamer, Lülüfer; Api, Hale; Yı̇ldırım, Hatice Kalkan; Baz, Kıymet; İkizoğlu, Güliz; Atik, Uğur

doi:10.1111/j.1365-4632.2007.02957.x

Cited by 9 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies on CYP2C19 polymorphisms have also been conducted in a Turkish population. In a study of 106 healthy volunteers, PM frequency was found to be 0.94% [23]. Aynacioglu et al, who found the PM frequency to be~1% [13], reported that the mutation responsible for the PM genotype was CYP2C19*2 and that there was no CYP2C19*3 in any of the individuals in the study.…”

Section: Discussionmentioning

confidence: 94%

Association of MDR1 , CYP2D6 , and CYP2C19 gene polymorphisms with prophylactic migraine treatment response

Atasayar

Eryılmaz

Karlı

et al. 2016

Journal of the Neurological Sciences

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 94%

Association of MDR1 , CYP2D6 , and CYP2C19 gene polymorphisms with prophylactic migraine treatment response

Atasayar

Eryılmaz

Karlı

et al. 2016

Journal of the Neurological Sciences

View full text Add to dashboard Cite

“…In a study from Turkey, Tursen et al [23] investigated CYP2C9*2 and *3 in 62 patients with BD as compared to 107 healthy controls and found no difference in the frequency of these alleles. No phenotype of CYP2C9, as our test with losartan, was performed and, therefore, the CYP2C9 activity in these 62 patients is unknown.…”

Section: Discussionmentioning

confidence: 99%

Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9

Helldén

Bergman

Hellgren

et al. 2010

Eur J Clin Pharmacol

View full text Add to dashboard Cite

Purpose The cytochrome P450 enzyme CYP2C9 metabolizes several important drugs, such as warfarin and oral antidiabetic drugs. The enzyme is polymorphic, and all known alleles, for example, CYP2C9*2 and*3, give decreased activity. Ultra-high activity of the enzyme has not yet been reported. Methods We present a patient with Behçet's disease who required treatment with high doses of phenytoin. When fluconazole, a potent inhibitor of CYP2C9, was added to the treatment regimen, the patient developed ataxia, tremor, fatigue, slurred speech and somnolence, indicating phenytoin intoxication. On suspicion of ultra-high activity of CYP2C9, a phenotyping test for CYP2C9 with losartan was performed.Results The patient was shown to have a higher activity of CYP2C9 than any of the 190 healthy Swedish Caucasians used as controls. Conclusions Our finding of an ultrarapid metabolism of losartan and phenytoin may apply to other CYP2C9 substrates, where inhibition of CYP2C9 may cause severe adverse drug reactions.

show abstract

“…Bu mutasyon allelerinin enzim kapasitesi hızlı metabolizör olarak da adlandırılan yabanıl tipe göre düşüktür (106). Türk popülasyonunda CYP2C9*2 ve CYP2C9*3 polimorfizminin BH ile ilişkisi araştırılmış ve bir anlamlılık olmadığı kaydedilmiştir (107). CYP2C19'daki mutasyonlar da enzim aktivitesindeki azalma ile ilişkilidir.…”

Section: Biyotransformasyon Enzimleriunclassified

Investigations of genetic polymorphisms related to Behcet\s disease in Turkish population

Oğuz¹,

Demiryürek²,

Alaşehirli³

et al. 2014

Gaziantep Med J

View full text Add to dashboard Cite

It is known that genetic variations are associated with some diseases and increase developing of some diseases while decrease some of them. The recent studies show that genetic polymorphisms have a role on susceptibility and prognosis of Behçet's disease (BD). Knowing the polymorphisms associated with BD and the side of these associations will be useful for explaining the pathogenesis of the disease and to develop more effective therapies. In this review we aimed to overview the recent studies investigated the polimorphisms which may have a role in BD in Turkish population.

show abstract

Cytochrome P450 polymorphisms in patients with Behcet's disease

Abstract: We observed that patients with BD presented with a higher prevalence of the heterozygous CYP2C19*2 genotype. Hereditary deficiencies of this enzyme activity may lead to an imbalance between pro- and antioxidant systems, resulting in the formation of excessive reactive oxygen species.

Cited by 9 publications

References 14 publications

Association of MDR1 , CYP2D6 , and CYP2C19 gene polymorphisms with prophylactic migraine treatment response

Association of MDR1 , CYP2D6 , and CYP2C19 gene polymorphisms with prophylactic migraine treatment response

Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9

Investigations of genetic polymorphisms related to Behcet\s disease in Turkish population

Contact Info

Product

Resources

About